

Nycodenz® Application Sheets

C44 Isolation of cells from lung tissue: rat alveolar type II pneumocytes

- ◆ For links to other relevant files click on the double blue arrow in the following text
- ◆ For the isolation of alveolar type I epithelial cells, the separation of alveolar endothelial and epithelial cells and alveolar macrophages see Application Sheet C25 →→

1. Background

Alveolar (pneumocyte) type II pneumocytes are widely studied because they synthesize and secrete the phospholipid-rich lung surfactant, which lines the air-alveolar interface and prevents alveolar collapse by lowering surface tension at low lung volumes. Isolation of these cells from both adult and foetal lung is an important prerequisite for the culture and study. Viscardi et al [1], who successfully developed a Nycodenz® gradient technique, emphasised the importance of the non-toxic, non-invasive properties of this gradient medium and pointed out that although Percoll® gradients had been used previously for purifying these cells, the potentially toxic nature of a polyvinyl-pyrrolidone-coated silica colloid was of considerable concern in studies of their function.

Viscardi et al [1] reported that the purity of type II pneumocytes from adult lung on Nycodenz® gradients was over 80%; very similar figures were obtained from foetal lung tissue. The recovery of these cells from adult lung was over 70%, while for foetal lung this figure was rather lower at 45-50%. Both the purity and the viability of the cells (approx. 97%) from Nycodenz® gradients were considerably higher than that obtained from cells purified by IgG panning. The cells from Nycodenz® gradients moreover had almost four times the plating efficiency. Other workers [2-4] have reported an even higher purity of >90% for the cells from foetal lung tissue. The same gradient system has also been used by Driscoll et al [5,6] and Johnston et al [7].

- ◆ Recently discontinuous iodixanol gradients have been used to purify these cells [8-9]

2. Preparation of cell suspension

The treatment of the lung tissue prior to gradient centrifugation is a complex operation, the detail of which varies from laboratory to laboratory and is outside the scope of this Application Sheet. For detailed information see refs 2-8. Briefly the preparation of the cell suspension involves five steps:

1. Rats are anaesthetized and heparin injected as an anticoagulant.
2. After tracheostomy the vasculature is perfused with a buffered saline medium such as 140 mM NaCl, 5 mM KCl, 2.5 mM Na₂HPO₄, 10 mM HEPES, 2.0 mM CaCl₂, 1.3 mM MgSO₄, pH 7.4 to remove blood cells [1]. Sometimes this is supplemented with glucose, nystatin and an antibiotic-antimycotic [7].
3. To remove macrophages, the lungs are lavaged several times with 140 mM NaCl, 5 mM KCl, 2.5 mM Na₂HPO₄, 10 mM HEPES, 6 mM glucose, 0.2 mM EGTA, pH 7.4 followed by lavage with the Step 2 buffer [1]. Sometimes the lavage procedure uses the Step 2 buffer (minus divalent cations) followed by Step 2 buffer [7].
4. Partial disaggregation of the cells by lavage with either elastase [1] or pronase [7]
5. After removal of the trachea, the lung tissue is minced in a solution containing DNase I (in Step 2 buffer) and foetal bovine serum and then incubated at 37°C for 5 min in a trypsinizing flask [1].

3. Cell fractionation

The following protocol is adapted from ref 1.

3a. Solutions required (see Note 1)

- A. Nycodenz® (60%, w/v) stock solution
- B. Nycoprep™ Diluent 1: 6 mM KCl, 0.6 mM EDTA, 10 mM HEPES-NaOH, pH 7.5
- C. Working Solution Diluent 2: 0.75% (w/v) NaCl, 3 mM KCl, 0.3 mM EDTA, 5 mM HEPES-NaOH, pH 7.5

3b. Protocol

1. Dilute Solution 27.6 vol. of Solution A with 32.4 vol. of Solution B to produce a solution containing 27.6% (w/v) Nycodenz® Working solution.
2. Dilute the Working Solution with Solution C to produce a 4.6% (w/v) Nycodenz® solution for a continuous gradient or three solutions of 20.7%, 13.8% and 4.6% Nycodenz® for a discontinuous gradient (see Note 2).
3. Filter the lung tissue (in approx 25 ml buffer) sequentially through 2- and 4-ply cotton gauze, followed by 100-, 37- and 15-µm nylon mesh.
4. Dilute with cell suspension buffer to 50 ml and centrifuge at 130 g for 10 min (see Note 3).
5. Suspend the cell pellets in DMEM containing 2% foetal bovine serum.
6. Produce a continuous Nycodenz® gradient of 1.03-1.15 g/ml using a two-chamber gradient maker or a Gradient Master™ using 4 ml each of the 27.6% and 4.6% Nycodenz® solutions.
7. **Alternatively** produce a discontinuous gradient from 2 ml each the 27.6%, 20.7%, 13.8% and 4.6% Nycodenz® solutions (see Step 2) by underlayering from a syringe and metal cannula and allow a continuous gradient to form by diffusion (see Notes 4-6).
8. Layer 3 ml of the cell suspension (approx 1×10^7 cells/ml) on top of the gradient.
9. Centrifuge at 1500 g for 20 min at 15°C.
10. Harvest the band of cells (at approx. 1.056 g/ml) just below the sample/gradient interface (see Note 7).

3c. Notes

1. Keeping Nycodenz® as a sterile stock solution of 60% (w/v) in water is a convenient source for preparation of a broad range of gradients. Make the stock solution by adding the powder slowly to water at approx 60°C while stirring, then allow the solution to cool to room temperature before making up to the desired volume. Its refractive index should be 1.4318 and its density 1.31 g/ml. Sterilize the solution by filtration.
2. See Steps 6 and 7 for information about choice of gradient solution preparation.
3. This pelleting step is sometimes carried out at higher g-forces, e.g. 500 g [7].
4. Metal “filling” cannulas can be obtained from any hospital supplies company.
5. If the tube is capped and carefully rotated to a horizontal position, diffusion to form a linear gradient will occur in about 1 h at room temperature. If the tube is maintained in a vertical position this process will take at least 6 h. It is always advisable to check that the density gradient

Keep the following stock solutions at 4°C
100 mM HEPES (free acid): 2.38 g per 100 ml water; adjust to pH 7.4 with 1 M NaOH before making up to final volume.

100 mM EDTA (Na₂•2H₂O) 3.72 g per 100 ml water
1 M KCl: 7.46 g per 100 ml water

Solution B: To 50 ml of water add 10 ml of the HEPES stock solution and 0.6 ml of both the KCl and EDTA stock solutions; adjust to pH 7.4 and make up to 100 ml with water

Solution C: Dissolve 0.75 g NaCl in 50 ml of water; add 5 ml of the HEPES stock solution and 0.3 ml of both the KCl and EDTA stock solutions; adjust to pH 7.4 and make up to 100 ml with water

is linear by unloading the gradient in a series of equal volume fractions and determining their density by measuring the refractive index or absorbance. For more information about the preparation gradients see ref 10 and [Basic Techniques File 2a](#) →→

6. In recent publications by Manzer et al [8] and Wang et al [9] a simple two layer gradient of iodixanol of densities 1.040 and 1.080 g/ml were described for the partial purification of Type II alveolar cells prior to further purification by negative selection with magnetic beads. Iodixanol is available as a sterile solution of density 1.32 g/ml (OptiPrep™) and it considerably simplifies gradient solution preparation. If an ordinary balanced salt or buffered saline solution is used to dilute the OptiPrep™, then these two densities are equivalent to approx 6.5% and 14% (w/v) iodixanol, i.e. OptiPrep™:diluent ratios of 6.5:53.5 and 14:46.
7. The broad band at approx. 1.086 g/ml contains fibroblasts, endothelial cells and macrophages, while any erythrocytes band close to the bottom of the gradient.

7. References

To access abstracts of refs 1-10 (file CA44) click on the double blue arrow →→

1. Viscardi, R. M., Ullsperger, S. and Resau, J. H. (1992) *Reproducible isolation of Type II pneumocytes from fetal and adult rat lung using Nycodenz gradients* Exp. Lung Res., **18**, 225-245
2. Torday, J. S., Sun, H. and Qin, J. (1998) *Prostaglandin E₂ integrates the effects of fluid distension and glucocorticoid on lung maturation* Am. J. Physiol. Lung Cell. Mol. Physiol., **274**, L106-L111
3. Schultz, C. J., Torres, E., Londos, C. and Torday, J. S. (2002) *Role of adipocyte differentiation-related protein in surfactant phospholipids synthesis* Am. J. Physiol. Lung Cell. Mol. Physiol., **283**, L288-L296
4. Torday, J. S. (2003) *Parathyroid hormone-related protein is a gravisensor in lung and bone cell biology* Adv. Space Res., **32**, 1569-1576
5. Driscoll, K. E., Deyo, L. C., Howard, B. W., Poynter, J. and Carter, J. M. (1995) *Characterizing mutagenesis in the hprt gene of rat alveolar epithelial cells* Exp. Lung Res., **21**, 941-956
6. Driscoll, K. E., Deyo, L. C., Carter, J. M., Howard, B. W., Hassenbein, D. G. and Bertram, T. A. (1997) *Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells* Carcinogenesis, **18**, 423-430
7. Johnston, C. J., Driscoll, K. E., Finkelstein, J. N., Baggs, R., O'Reilly, M. A., Carter, J., Gelein, R. and Oberdorster, G. (2000) *Pulmonary chemokine and mutagenic responses in rats after subchronic inhalation of amorphous and crystalline silica* Toxicol. Sci., **56**, 405-413
8. Manzer, R., Wang, J., Nishina, K., McConville, G. and Mason, R.J. (2006) *Alveolar epithelial cells secrete chemokines in response to IL-1 β and lipopolysaccharide but not to ozone* Am. J. Respir. Cell Mol., **34**, 158-166
9. Wang, J., Edeen, K., Manzer, R., Chang, Y., Wang, S., Chen, X., Funk, C.J., Cosgrove, G.P., Fang, X. and Mason, R.J. (2007) *Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro* Am. J. Respir. Cell Mol. Biol., **36**, 661-668
10. Graham, J. M. (2001) *Gradient techniques* in Biological Centrifugation, Taylor and Francis Books Ltd, Oxford, UK, pp 61-83